Mast Accelerates Enrollment In Pivotal Sickle Cell Study Of MST-188
This article was originally published in Pharmaceutical Approvals Monthly
With enrollment finally ramping up in trial open to older patients, Mast Therapeutics envisions a broad labeling horizon for MST-188, after a very long development road.
You may also be interested in...
Shares in Mast Therapeutics dropped by more than 80% upon news that a Phase III trial of its lead product vepoloxamer in sickle cell disease had failed.
As interest in drugs with orphan indications picks up and the science advances, sickle cell disease is attracting the attention of big pharma, with deals inked for two promising therapeutics and a variety of approaches in the clinic with partnership potential.
Formerly called Adventrx, the company says the name Mast better reflects its current strategy, which includes a focus on a Phase III asset for sickle cell disease. With a new name and a late-stage trial underway, management is hoping to persuade skeptical investors to take a second look.